FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310295772> ?p ?o ?g. }

• W4310295772 abstract "Abstract Background Adherence to antiretroviral treatment (ART) remains the cornerstone of optimal HIV outcomes, including viral suppression (VS), immune recovery, and decreased transmission risk. For many people with HIV (PWH), particularly those with early-acquired HIV, structural, behavioral, and cognitive barriers to adherence and competing priorities related to life events may be difficult to overcome, resulting in nonadherence. Long-acting injectable antiretroviral therapies (LAI-ART) may be a useful strategy to overcome some of these barriers. However, to date, the approved LAI-ART strategies (e.g., cabotegravir and rilpivirine (CAB/RPV)) have targeted those who have already attained viral suppression, precluding their use in the 40% of adolescents and young adults (AYA) that VS has eluded. Case presentation Ms. X is a 30-year-old woman with perinatally-acquired HIV and barriers to adherence. Despite many interventions, she remained persistently viremic, with resultant immune suppression and multiple comorbid opportunistic conditions, and viral load (VL) > 10,000,000 copies/ml. Given her longstanding history of poor adherence to an oral regimen, a switch to monthly intramuscular (IM) injections and biweekly infusions of ibalizumab were initiated leading to decreased viral load to 8,110 copies/ml within two weeks. Ms. H is a 33-year-old woman with cognitive limitations due to childhood lead poisoning. Her viral load trajectory took a downward turn, precipitated by various life events, remaining elevated despite intensive case management. Initiation of LAI-ART (CAB/RPV) in this patient led to an undetectable VL (< 20 copies/ml) within two months of treatment initiation. Miss Y. is a 37-year-old woman with perinatally-acquired HIV and chronic challenges with nonadherence and longstanding immunosuppression with CD4 < 200 cells/mm 3 for > 5 years. She received a 1-month oral lead-in (OLI) of cabotegravir/rilpivirine, followed by the injectable loading dose. She has since adhered to all her monthly dosing appointments, sustained VS, and transitioned to a bi-monthly injection schedule. Conclusion These three individuals with HIV (perinatally and non-perinatally acquired) with longstanding nonadherence and persistent viremia were successfully initiated on LAI-ART through the process of care coordination and the collective efforts of the care team, highlighting the barriers, challenges, and the multidisciplinary coordination needed to assure successful implementation of this strategy for the most vulnerable of patients." @default.
• W4310295772 created "2022-11-30" @default.
• W4310295772 creator A5004446586 @default.
• W4310295772 creator A5007514947 @default.
• W4310295772 creator A5023483564 @default.
• W4310295772 creator A5048622777 @default.
• W4310295772 creator A5050961977 @default.
• W4310295772 creator A5052419206 @default.
• W4310295772 creator A5060676573 @default.
• W4310295772 creator A5074143221 @default.
• W4310295772 creator A5078565997 @default.
• W4310295772 creator A5078950002 @default.
• W4310295772 creator A5079027192 @default.
• W4310295772 date "2022-11-26" @default.
• W4310295772 modified "2023-09-26" @default.
• W4310295772 title "Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series" @default.
• W4310295772 cites W2617514227 @default.
• W4310295772 cites W2764202206 @default.
• W4310295772 cites W2767883430 @default.
• W4310295772 cites W2900479433 @default.
• W4310295772 cites W2900507634 @default.
• W4310295772 cites W2959479568 @default.
• W4310295772 cites W2964855751 @default.
• W4310295772 cites W3006677066 @default.
• W4310295772 cites W3009494891 @default.
• W4310295772 cites W3157916043 @default.
• W4310295772 cites W3215180580 @default.
• W4310295772 cites W4226038398 @default.
• W4310295772 cites W4288063375 @default.
• W4310295772 cites W4292438841 @default.
• W4310295772 cites W3090178505 @default.
• W4310295772 doi "https://doi.org/10.1186/s12981-022-00477-w" @default.
• W4310295772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36435793" @default.
• W4310295772 hasPublicationYear "2022" @default.
• W4310295772 type Work @default.
• W4310295772 citedByCount "2" @default.
• W4310295772 countsByYear W43102957722023 @default.
• W4310295772 crossrefType "journal-article" @default.
• W4310295772 hasAuthorship W4310295772A5004446586 @default.
• W4310295772 hasAuthorship W4310295772A5007514947 @default.
• W4310295772 hasAuthorship W4310295772A5023483564 @default.
• W4310295772 hasAuthorship W4310295772A5048622777 @default.
• W4310295772 hasAuthorship W4310295772A5050961977 @default.
• W4310295772 hasAuthorship W4310295772A5052419206 @default.
• W4310295772 hasAuthorship W4310295772A5060676573 @default.
• W4310295772 hasAuthorship W4310295772A5074143221 @default.
• W4310295772 hasAuthorship W4310295772A5078565997 @default.
• W4310295772 hasAuthorship W4310295772A5078950002 @default.
• W4310295772 hasAuthorship W4310295772A5079027192 @default.
• W4310295772 hasBestOaLocation W43102957721 @default.
• W4310295772 hasConcept C118552586 @default.
• W4310295772 hasConcept C119599485 @default.
• W4310295772 hasConcept C126322002 @default.
• W4310295772 hasConcept C127413603 @default.
• W4310295772 hasConcept C140206745 @default.
• W4310295772 hasConcept C142462285 @default.
• W4310295772 hasConcept C177713679 @default.
• W4310295772 hasConcept C187212893 @default.
• W4310295772 hasConcept C203014093 @default.
• W4310295772 hasConcept C27415008 @default.
• W4310295772 hasConcept C2781413609 @default.
• W4310295772 hasConcept C2993143319 @default.
• W4310295772 hasConcept C3013748606 @default.
• W4310295772 hasConcept C3019165603 @default.
• W4310295772 hasConcept C71924100 @default.
• W4310295772 hasConcept C761482 @default.
• W4310295772 hasConceptScore W4310295772C118552586 @default.
• W4310295772 hasConceptScore W4310295772C119599485 @default.
• W4310295772 hasConceptScore W4310295772C126322002 @default.
• W4310295772 hasConceptScore W4310295772C127413603 @default.
• W4310295772 hasConceptScore W4310295772C140206745 @default.
• W4310295772 hasConceptScore W4310295772C142462285 @default.
• W4310295772 hasConceptScore W4310295772C177713679 @default.
• W4310295772 hasConceptScore W4310295772C187212893 @default.
• W4310295772 hasConceptScore W4310295772C203014093 @default.
• W4310295772 hasConceptScore W4310295772C27415008 @default.
• W4310295772 hasConceptScore W4310295772C2781413609 @default.
• W4310295772 hasConceptScore W4310295772C2993143319 @default.
• W4310295772 hasConceptScore W4310295772C3013748606 @default.
• W4310295772 hasConceptScore W4310295772C3019165603 @default.
• W4310295772 hasConceptScore W4310295772C71924100 @default.
• W4310295772 hasConceptScore W4310295772C761482 @default.
• W4310295772 hasIssue "1" @default.
• W4310295772 hasLocation W43102957721 @default.
• W4310295772 hasLocation W43102957722 @default.
• W4310295772 hasLocation W43102957723 @default.
• W4310295772 hasLocation W43102957724 @default.
• W4310295772 hasLocation W43102957725 @default.
• W4310295772 hasOpenAccess W4310295772 @default.
• W4310295772 hasPrimaryLocation W43102957721 @default.
• W4310295772 hasRelatedWork W2079342860 @default.
• W4310295772 hasRelatedWork W2148977521 @default.
• W4310295772 hasRelatedWork W2157497799 @default.
• W4310295772 hasRelatedWork W2325711945 @default.
• W4310295772 hasRelatedWork W2613384466 @default.
• W4310295772 hasRelatedWork W2911784407 @default.
• W4310295772 hasRelatedWork W2912123654 @default.
• W4310295772 hasRelatedWork W2954379987 @default.
• W4310295772 hasRelatedWork W2987747606 @default.
• W4310295772 hasRelatedWork W4299359817 @default.

• next